Bispecific CD30/CD16A Diabody for NK Cell Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NK cell-based immunotherapies face challenges in effectively activating and sustaining the cytotoxicity of naive NK cells against cancer cells, particularly in environments with high serum IgG levels and competitive binding to CD16A, limiting the full potential of antibody-dependent cellular cytotoxicity (ADCC).
Innovation Solution
The use of bispecific and tetravalent tandem diabodies, such as CD30/CD16A, EGFR/CD16A, and BCMA/CD16A, which intermittently engage NK cells with CD16A, combined with cytokines like IL-2 or IL-15, to enhance NK cell activation and memory-like functionality, allowing for improved recognition and killing of tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic antibodies are used to engage CD16A on NK cells, then ADCC activity is activated, but high serum IgG levels in myeloma patients cause competition for CD16A binding and reduce effectiveness
Solution Approach 1:
The patent uses a bispecific tandem diabody as an intermediary molecule that bridges the target antigen (CD30) and the effector cell (NK cell via CD16A). This diabody format provides Fc-independent CD16A engagement, eliminating competition with endogenous IgG while maintaining ADCC activity. The diabody's unique structure allows it to bind CD16A through its variable regions rather than Fc regions, serving as a mediator that bypasses the blocking effect of high serum IgG levels.
Solution Approach 2:
The patent changes the binding parameters by using a diabody format with altered affinity characteristics for CD16A. The tandem diabody exhibits high affinity and avidity for CD16A through its bispecific design, with kinetic parameters optimized to overcome the competitive inhibition by serum IgG. This parameter change in binding affinity and mechanism allows effective engagement despite the presence of high levels of endogenous antibodies.
2Productivity
If NK cells are continuously exposed to antigen binding protein, then initial cytotoxicity is activated, but transient selective reduction in cytotoxic potency occurs
Solution Approach 1:
The patent implements periodic administration of the antigen binding protein rather than continuous exposure. This periodic dosing regimen allows NK cells to recover from transient dysfunction between doses while maintaining activated phenotypes. The intermittent exposure re-stimulates NK cells and restores CD16A expression and cytotoxic potency, creating a rhythm of activation and recovery that sustains overall anti-tumor activity.
Solution Approach 2:
The patent embraces the dynamic nature of NK cell response by allowing the system to transition between activated and recovered states. Rather than attempting to maintain static continuous activation, the approach dynamically adjusts NK cell engagement through periodic protein administration, allowing natural fluctuations in CD16A expression and cytotoxic function that ultimately sustain potency over time.
3Measurement precision
If high affinity CD16A engagement is achieved through Fc-independent binding, then CD16A affinity is improved, but transient reduction in NK cell function occurs upon exposure
Solution Approach 1:
The patent uses periodic re-administration of the high affinity antigen binding protein to restore NK cell function after transient reduction. The intermittent dosing allows NK cells to recover CD16A expression and cytotoxic function between exposures, while each subsequent exposure re-engages the high affinity binding to reactivate NK cells. This periodic pattern maintains both high affinity engagement and reliable NK cell function over time.
Data Source
Figure 1A~1B
Figure 1C
Figure 1D~1E
AI summary
The invention relates to an anti-CD16A antigen binding protein for use in NK cell based immunotherapy, wherein the anti-CD16A antigen binding protein is to be administered intermittently and in combination with a cytokine. In certain embodiments the antigen binding protein is a tetravalent and bispecific CD30/CD16A tandem diabody.